FGFR4 and hepatocellular carcinoma: A Phase 1/2 open‐label study (CFGF401X2101 trial; NCT02325739) evaluating the safety and efficacy of FGF401 in patients with HCC or solid tumors with positive FGFR4 and KLB expression was the precursor to this study.28